Skip to main content
Erschienen in: Breast Cancer Research and Treatment 3/2010

01.08.2010 | Epidemiology

Variants in DNA double-strand break repair genes and risk of familial breast cancer in a South American population

verfasst von: Lilian Jara, Karen Dubois, Daniel Gaete, Tomas de Mayo, Nikalai Ratkevicius, Teresa Bravo, Sonia Margarit, Rafael Blanco, Fernando Gómez, Enrique Waugh, Octavio Peralta, Jose M. Reyes, Gladys Ibáñez, Patricio González-Hormazábal

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 3/2010

Einloggen, um Zugang zu erhalten

Abstract

The double-strand break (DSB) DNA repair pathway has been implicated in breast cancer (BC). RAD51 and its paralogs XRCC3 and RAD51D play an important role in the repair of DSB through homologous recombination (HR). Some polymorphisms including XRCC3-Thr241Met, RAD51-135G>C, and RAD51D-E233G have been found to confer increased BC susceptibility. In order to detect novel mutations that may contribute to BC susceptibility, 150 patients belonging to 150 Chilean BRCA1/2-negative families were screened for mutations in XRCC3. No mutations were detected in the XRCC3 gene. In addition, using a case–control design we studied the XRCC3-Thr241Met, and RAD51D-E233G polymorphisms in 267 BC cases and 500 controls to evaluate their possible association with BC susceptibility. The XRCC3 Met/Met genotype was associated with an increased BC risk (P = 0.003, OR = 2.44 [95%CI 1.34–4.43]). We did not find an association between E233G polymorphism and BC risk. We also analyzed the effect of combined genotypes among RAD51-135G>C, Thr241Met, and E233G polymorphisms on BC risk. No interaction was observed between Thr241Met and 135G>C. The combined genotype Thr/Met–E/G was associated with an increased BC risk among women who (a) have a family history of BC, (b) are BRCA1/2-negative, and (c) were <50 years at onset (n = 195) (P = 0.037, OR = 10.5 [95%CI 1.16–94.5]). Our results suggested that the variability of the DNA HR repair genes XRCC3 and RAD51D may play a role in BC risk, but this role may be underlined by a mutual interaction between these genes. These findings should be confirmed in other populations.
Literatur
2.
Zurück zum Zitat Peralta O, Jorquera A, Rencoret C et al (1995) Cáncer de mama: resultados del programa de pesquisa y tratamiento del Servicio de Salud Central. Rev Chil Obstet Ginecol 60(6):417. doi:10.4067/S0717-75262002000600002 Peralta O, Jorquera A, Rencoret C et al (1995) Cáncer de mama: resultados del programa de pesquisa y tratamiento del Servicio de Salud Central. Rev Chil Obstet Ginecol 60(6):417. doi:10.​4067/​S0717-7526200200060000​2
4.
Zurück zum Zitat Prieto M (2006) Situación epidemiológica del cáncer de mama en Chile 1994–2003. Rev Med Clin Condes 17(4):142–148 Prieto M (2006) Situación epidemiológica del cáncer de mama en Chile 1994–2003. Rev Med Clin Condes 17(4):142–148
9.
Zurück zum Zitat Kuschel B, Auranen A, McBride S et al (2002) Variants in DNA double-strand break repair genes and breast cancer susceptibility. Hum Mol Genet 11(12):1399–1407CrossRefPubMed Kuschel B, Auranen A, McBride S et al (2002) Variants in DNA double-strand break repair genes and breast cancer susceptibility. Hum Mol Genet 11(12):1399–1407CrossRefPubMed
10.
Zurück zum Zitat Levy-Lahad E, Lahad A, Eisenberg S et al (2001) A single nucleotide polymorphism in the RAD51 gene modifies cancer risk in BRCA2 but not BRCA1 carriers. Proc Natl Acad Sci USA 98(6):3232–3236CrossRefPubMed Levy-Lahad E, Lahad A, Eisenberg S et al (2001) A single nucleotide polymorphism in the RAD51 gene modifies cancer risk in BRCA2 but not BRCA1 carriers. Proc Natl Acad Sci USA 98(6):3232–3236CrossRefPubMed
11.
Zurück zum Zitat Wang WW, Spurdle AB, Kolachana P et al (2001) A single nucleotide polymorphism in the 5′ untranslated region of RAD51 and risk of cancer among BRCA1/2 mutation carriers. Cancer Epidemiol Biomark Prev 10(9):955–960 Wang WW, Spurdle AB, Kolachana P et al (2001) A single nucleotide polymorphism in the 5′ untranslated region of RAD51 and risk of cancer among BRCA1/2 mutation carriers. Cancer Epidemiol Biomark Prev 10(9):955–960
12.
Zurück zum Zitat Dufloth RM, Costa S, Schmitt F et al (2005) DNA repair gene polymorphisms and susceptibility to familial breast cancer in a group of patients from Campinas, Brazil. Genet Mol Res 4(4):771–782PubMed Dufloth RM, Costa S, Schmitt F et al (2005) DNA repair gene polymorphisms and susceptibility to familial breast cancer in a group of patients from Campinas, Brazil. Genet Mol Res 4(4):771–782PubMed
13.
Zurück zum Zitat Costa S, Pinto D, Pereira D et al (2007) DNA repair polymorphisms might contribute differentially on familial and sporadic breast cancer susceptibility: a study on a Portuguese population. Breast Cancer Res Treat 103(2):209–217. doi:10.1007/s10549-006-9364-z CrossRefPubMed Costa S, Pinto D, Pereira D et al (2007) DNA repair polymorphisms might contribute differentially on familial and sporadic breast cancer susceptibility: a study on a Portuguese population. Breast Cancer Res Treat 103(2):209–217. doi:10.​1007/​s10549-006-9364-z CrossRefPubMed
14.
Zurück zum Zitat Jacobsen NR, Nexo BA, Olsen A et al (2003) No association between the DNA repair gene XRCC3 T241M polymorphism and risk of skin cancer and breast cancer. Cancer Epidemiol Biomark Prev 12(6):584–585 Jacobsen NR, Nexo BA, Olsen A et al (2003) No association between the DNA repair gene XRCC3 T241M polymorphism and risk of skin cancer and breast cancer. Cancer Epidemiol Biomark Prev 12(6):584–585
15.
Zurück zum Zitat Smith TR, Levine EA, Perrier ND et al (2003) DNA-repair genetic polymorphisms and breast cancer risk. Cancer Epidemiol Biomark Prev 12(11 Pt 1):1200–1204 Smith TR, Levine EA, Perrier ND et al (2003) DNA-repair genetic polymorphisms and breast cancer risk. Cancer Epidemiol Biomark Prev 12(11 Pt 1):1200–1204
17.
Zurück zum Zitat Figueiredo JC, Knight JA, Briollais L et al (2004) Polymorphisms XRCC1-R399Q and XRCC3-T241M and the risk of breast cancer at the Ontario site of the Breast Cancer Family Registry. Cancer Epidemiol Biomark Prev 13(4):583–591 Figueiredo JC, Knight JA, Briollais L et al (2004) Polymorphisms XRCC1-R399Q and XRCC3-T241M and the risk of breast cancer at the Ontario site of the Breast Cancer Family Registry. Cancer Epidemiol Biomark Prev 13(4):583–591
18.
Zurück zum Zitat Han J, Hankinson SE, Hunter DJ et al (2004) Genetic variations in XRCC2 and XRCC3 are not associated with endometrial cancer risk. Cancer Epidemiol Biomark Prev 13(2):330–331CrossRef Han J, Hankinson SE, Hunter DJ et al (2004) Genetic variations in XRCC2 and XRCC3 are not associated with endometrial cancer risk. Cancer Epidemiol Biomark Prev 13(2):330–331CrossRef
19.
Zurück zum Zitat Forsti A, Angelini S, Festa F et al (2004) Single nucleotide polymorphisms in breast cancer. Oncol Rep 11(4):917–922PubMed Forsti A, Angelini S, Festa F et al (2004) Single nucleotide polymorphisms in breast cancer. Oncol Rep 11(4):917–922PubMed
20.
Zurück zum Zitat Webb PM, Hopper JL, Newman B et al (2005) Double-strand break repair gene polymorphisms and risk of breast or ovarian cancer. Cancer Epidemiol Biomark Prev 14(2):319–323CrossRef Webb PM, Hopper JL, Newman B et al (2005) Double-strand break repair gene polymorphisms and risk of breast or ovarian cancer. Cancer Epidemiol Biomark Prev 14(2):319–323CrossRef
21.
Zurück zum Zitat Rodriguez-Lopez R, Osorio A, Ribas G et al (2004) The variant E233G of the RAD51D gene could be a low-penetrance allele in high-risk breast cancer families without BRCA1/2 mutations. Int J Cancer 110(6):845–849. doi:10.1002/ijc.20169 CrossRefPubMed Rodriguez-Lopez R, Osorio A, Ribas G et al (2004) The variant E233G of the RAD51D gene could be a low-penetrance allele in high-risk breast cancer families without BRCA1/2 mutations. Int J Cancer 110(6):845–849. doi:10.​1002/​ijc.​20169 CrossRefPubMed
22.
Zurück zum Zitat Dowty JG, Lose F, Jenkins MA et al (2008) The RAD51D E233G variant and breast cancer risk: population-based and clinic-based family studies of Australian women. Breast Cancer Res Treat 112(1):35–39. doi:10.1007/s10549-007-9832-0 CrossRefPubMed Dowty JG, Lose F, Jenkins MA et al (2008) The RAD51D E233G variant and breast cancer risk: population-based and clinic-based family studies of Australian women. Breast Cancer Res Treat 112(1):35–39. doi:10.​1007/​s10549-007-9832-0 CrossRefPubMed
26.
27.
Zurück zum Zitat Korkko J, Annunen S, Pihlajamaa TPD, Ala-Kokko L (1998) Conformation sensitive gel electrophoresis for simple and accurate detection of mutations: comparison with denaturing gradient gel electrophoresis and nucleotide sequencing. Proc Natl Acad Sci USA 95(4):1681–1685CrossRefPubMed Korkko J, Annunen S, Pihlajamaa TPD, Ala-Kokko L (1998) Conformation sensitive gel electrophoresis for simple and accurate detection of mutations: comparison with denaturing gradient gel electrophoresis and nucleotide sequencing. Proc Natl Acad Sci USA 95(4):1681–1685CrossRefPubMed
28.
Zurück zum Zitat Nataraj AJ, Olivos-Glander I, Kusukawa N et al (1999) Single-strand conformation polymorphism and heteroduplex analysis for gel-based mutation detection. Electrophoresis 20(6):1177–1185CrossRefPubMed Nataraj AJ, Olivos-Glander I, Kusukawa N et al (1999) Single-strand conformation polymorphism and heteroduplex analysis for gel-based mutation detection. Electrophoresis 20(6):1177–1185CrossRefPubMed
30.
Zurück zum Zitat Perry DJ, Carrell RW (1992) Hydrolink gels—a rapid and simple approach to the detection of DNA mutations in thromboembolic disease. J Clin Pathol 45(2):158–160CrossRefPubMed Perry DJ, Carrell RW (1992) Hydrolink gels—a rapid and simple approach to the detection of DNA mutations in thromboembolic disease. J Clin Pathol 45(2):158–160CrossRefPubMed
31.
Zurück zum Zitat Soto D, Sukumar S (1992) Improved detection of mutations in the p53 gene in human tumors as single-stranded conformation polymorphs and double-stranded heteroduplex DNA. Genome Res 2(1):96–98. doi:10.1101/gr.2.1.96 CrossRef Soto D, Sukumar S (1992) Improved detection of mutations in the p53 gene in human tumors as single-stranded conformation polymorphs and double-stranded heteroduplex DNA. Genome Res 2(1):96–98. doi:10.​1101/​gr.​2.​1.​96 CrossRef
32.
Zurück zum Zitat Perkins EJ, Nair A, Cowley DO et al (2002) Sensing of intermediates in V(D)J recombination by ATM. Genes Dev 16(2):159–164CrossRefPubMed Perkins EJ, Nair A, Cowley DO et al (2002) Sensing of intermediates in V(D)J recombination by ATM. Genes Dev 16(2):159–164CrossRefPubMed
34.
Zurück zum Zitat Garcia-Closas M, Egan KM, Newcomb PA et al (2006) Polymorphisms in DNA double-strand break repair genes and risk of breast cancer: two population-based studies in USA and Poland, and meta-analyses. Hum Genet 119(4):376–388. doi:10.1007/s00439-006-0135-z CrossRefPubMed Garcia-Closas M, Egan KM, Newcomb PA et al (2006) Polymorphisms in DNA double-strand break repair genes and risk of breast cancer: two population-based studies in USA and Poland, and meta-analyses. Hum Genet 119(4):376–388. doi:10.​1007/​s00439-006-0135-z CrossRefPubMed
35.
Zurück zum Zitat Breast Cancer Association Consortium (2006) Commonly studied single-nucleotide polymorphisms and breast cancer: results from the Breast Cancer Association Consortium. J Natl Cancer Inst 98(19):1382–1396. doi:10.1093/jnci/djj374 CrossRef Breast Cancer Association Consortium (2006) Commonly studied single-nucleotide polymorphisms and breast cancer: results from the Breast Cancer Association Consortium. J Natl Cancer Inst 98(19):1382–1396. doi:10.​1093/​jnci/​djj374 CrossRef
36.
Zurück zum Zitat Cruz-Coke R (1976) Origen y evolución étnica de la población chilena. Rev Med Chile 101:365–368 Cruz-Coke R (1976) Origen y evolución étnica de la población chilena. Rev Med Chile 101:365–368
37.
Zurück zum Zitat Valenzuela CY, Harb Z (1977) Socioeconomic assortative mating in Santiago, Chile: as demonstrated using stochastic matrices of mother-child relationships applied to ABO blood groups. Soc Biol 24:225–233PubMed Valenzuela CY, Harb Z (1977) Socioeconomic assortative mating in Santiago, Chile: as demonstrated using stochastic matrices of mother-child relationships applied to ABO blood groups. Soc Biol 24:225–233PubMed
38.
Zurück zum Zitat Valenzuela CY, Acuña M, Harb Z (1987) Gradiente sociogenético en la población chilena. Rev Med Chile 115:295–299PubMed Valenzuela CY, Acuña M, Harb Z (1987) Gradiente sociogenético en la población chilena. Rev Med Chile 115:295–299PubMed
39.
Zurück zum Zitat Valenzuela CY (1988) On sociogenetic clines. Ethol Sociobiol 9(5):259–268CrossRef Valenzuela CY (1988) On sociogenetic clines. Ethol Sociobiol 9(5):259–268CrossRef
41.
Zurück zum Zitat Schwartz GF, Hughes KS, Lynch HT et al (2008) Proceedings of the international consensus conference on breast cancer risk, genetics, & risk management, April, 2007. Cancer 113(10):2627–2637. doi:10.1002/cncr.23903 CrossRefPubMed Schwartz GF, Hughes KS, Lynch HT et al (2008) Proceedings of the international consensus conference on breast cancer risk, genetics, & risk management, April, 2007. Cancer 113(10):2627–2637. doi:10.​1002/​cncr.​23903 CrossRefPubMed
43.
Metadaten
Titel
Variants in DNA double-strand break repair genes and risk of familial breast cancer in a South American population
verfasst von
Lilian Jara
Karen Dubois
Daniel Gaete
Tomas de Mayo
Nikalai Ratkevicius
Teresa Bravo
Sonia Margarit
Rafael Blanco
Fernando Gómez
Enrique Waugh
Octavio Peralta
Jose M. Reyes
Gladys Ibáñez
Patricio González-Hormazábal
Publikationsdatum
01.08.2010
Verlag
Springer US
Erschienen in
Breast Cancer Research and Treatment / Ausgabe 3/2010
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-009-0709-2

Weitere Artikel der Ausgabe 3/2010

Breast Cancer Research and Treatment 3/2010 Zur Ausgabe

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

16.05.2024 alpha-1-Rezeptorantagonisten Nachrichten

Nach einer Prostatabiopsie treten häufig Probleme beim Wasserlassen auf. Ob sich das durch den periinterventionellen Einsatz von Alphablockern verhindern lässt, haben australische Mediziner im Zuge einer Metaanalyse untersucht.

Antikörper-Wirkstoff-Konjugat hält solide Tumoren in Schach

16.05.2024 Zielgerichtete Therapie Nachrichten

Trastuzumab deruxtecan scheint auch jenseits von Lungenkrebs gut gegen solide Tumoren mit HER2-Mutationen zu wirken. Dafür sprechen die Daten einer offenen Pan-Tumor-Studie.

Mammakarzinom: Senken Statine das krebsbedingte Sterberisiko?

15.05.2024 Mammakarzinom Nachrichten

Frauen mit lokalem oder metastasiertem Brustkrebs, die Statine einnehmen, haben eine niedrigere krebsspezifische Mortalität als Patientinnen, die dies nicht tun, legen neue Daten aus den USA nahe.

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

13.05.2024 Pankreaskarzinom Nachrichten

Gerade bei aggressiven Malignomen wie dem duktalen Adenokarzinom des Pankreas könnte Früherkennung die Therapiechancen verbessern. Noch jedoch klafft hier eine Lücke. Ein Studienteam hat einen Weg gesucht, sie zu schließen.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.